ArticlePloS one2026
Obtention and preliminary clinical evaluation of an equine albumin for intravenous administration in adult Colombian Creole Horses (Equus ferus caballus).
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin is one of the most abundant and physiologically important blood protein in horses due to its ability to regulate vascular volume and transport blood metabolites or drugs. Despite the importance of this protein, in Colombia there is no previous reference of the use of equine albumin in horses as a pharmacological therapy and there is no available any pharmaceutical preparation of this protein to be administrated in horses. This study aims to evaluate for first time the preliminary clinical response of healthy adult Colombian Creole horses after the intravenous administration of an equine albumin preparation, manufactured in Colombia. Equine albumin was prepared from the plasma of healthy horses and obtained through the modified Salting Out technique. The Standard Quality Characterization was carried out following World Health Organization standards which included physicochemical, sterility and hemotropics tests before being administered to the horses. Albumin was administered at a concentration of 5,334 mg per animal to 3 healthy horses that were clinically evaluated before, during and after albumin administration, recording different paraclinical and clinical parameters. After manufacturing, the equine albumin obtained fulfilled the quality characteristics to be administered intravenously. After the administration, the product did not generate any adverse reactions or adverse clinical alteration at the concentration used. During the clinical evaluation we were able to observe a plasma volume expansion. Results indicates the ability to obtain a high quality product that can potentially be used as a pharmacological therapy in horses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.